Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasofoxifene vs Raloxifene for Bone Loss Prevention (CORAL)
NCT00163137Phase 3Completed
- Sponsor
- Ligand Pharmaceuticals
- Start
- May 2003
- Primary completion
- Oct 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lasofoxifene in osteoporosis (3 arms), sponsored by Ligand Pharmaceuticals. Primary endpoint: Bone Mineral Density of the Lumbar Spine at 2 years. Started May 2003; status: completed.
02
Drugs
lasofoxifene
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00163137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00163137.